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Introduction
Sarcoidosis and hemoglobinopathies are 2 disorders commonly 
affecting the black population. Sarcoidosis occurs at a rate of 
about 30 to 40 per 100 000 in the general population, and 
approximately 0.15% of African Americans are homozygous 
and hence have sickle cell disease (SCD).1 We are reporting 
a patient with SCD who survived childhood to later develop 
sarcoidosis which caused liver impairment. When oral steroids 
were used to manage hepatic sarcoidosis, it precipitated sick-
ling. We could find no previous report in the published litera-
ture regarding guidance on management of such a patient. We 
realize this report raises more questions than answers but 
strongly believe these data need to be collected to formulate 
optimal care in patients with sickle cell hepatopathy or hepatic 
sarcoidosis or when they occur together.
Case Report
A 34-year-old African American man with known SCD on 
chronic exchange transfusions (secondary to stroke at the age 
of 6) was diagnosed with pulmonary and ocular sarcoid. He 
also had a history of atrial fibrillation, post defibrillator place-
ment for cardiomyopathy, and history of sudden cardiac deaths 
in the family and was on rivaroxaban.
He was initially started on low-dose prednisone and meth-
otrexate for sarcoidosis, which precipitated his first sickle cell 
crisis in more than a decade. He presented with pain and ane-
mia, with his hemoglobin falling from a baseline of 8 to 6 
g/dL requiring blood transfusions. His liver panel showed 
aspartate aminotransferase (AST) of 213 U/L, alanine ami-
notransferase (ALT) of 68 U/L, alkaline phosphatase of 373 
U/L, total bilirubin of 26.3 mg/dL, conjugated bilirubin of 
22.7 mg/dL, and international normalized ratio (INR) of 1.3. 
Liver biopsy showed exuberant granuloma with sinusoid sick-
ling. Rivaroxaban was changed to warfarin after discussion 
with the family, mainly for the convenience of monitoring and 
reversing coagulopathy if needed.
He was admitted within a year of initial diagnosis of sar-
coidosis for progressively worsening limb edema and ascites. 
Furosemide and spironolactone had minimal response. He had 
a large-volume paracentesis performed, which revealed no evi-
dence of spontaneous bacterial peritonitis. The appearance of 
Ascitic fluid was orange in color with total nucleated cells of 
26433/mm3 among which total nucleated cells were 60/mm3 L 
with 81% polymorphs. He was also found to be encephalo-
pathic, and lactulose was initiated. Other causes of acute liver 
failure, including paracetamol ingestion, were ruled out because 
the levels were undetectable. Also, the patient was never found 
to have adverse effects of incompatible blood transfusion. 
Hepatitis C virus was negative and serum albumin was 2.9 
mg/dL, with partial thromboplastin time elevated to more than 
150 during his whole hospital course. D-dimer was moderately 
increased. Hepatology continued to advocate for azathioprine. 
Warfarin was held secondary to coagulopathy. He developed a 
nose bleed for which he was treated with fresh frozen plasma 
and vitamin K with some resolution of symptoms. His Model 
for End-Stage Liver Disease was calculated at 35, but because 
he did not have cirrhosis these scores were inaccurate. He was 
transferred to the intensive care unit after he started bleeding 
from the site of his paracentesis and had to have purse string 
sutures placed. The patient continued to be in acute liver fail-
ure, and despite optimal supportive therapy, he developed an 
intracranial bleed with adverse outcome. During this time 
period, his INR reached up to 7.5 which was corrected down to 
3.1. International normalized ratio has been used here even 
after cessation of warfarin because it is a test for synthetic func-
tion too. Abdominal ultrasound during this period showed 
massive hemoperitoneum most prominent in the left lower 
quadrant. His AST peaked at 7922 U/L, ALT at 1389 U/L, 
alkaline phosphatase at 233 U/L, and total bilirubin at 
47.7 mg/dL, with direct bilirubin greater than 30 mg/dL 
during this hospital course.
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Discussion
Sarcoidosis and hemoglobinopathies are 2 disorders com-
monly affecting the African American population. The prev-
alence of sarcoidosis is largely dependent on race and ethnicity. 
The association of sarcoidosis and SCD has been reported in 
few cases.2
Although sarcoid granulomas are present in the liver on 
histopathology in patients with pulmonary disease, these 
granulomas causing an abnormal liver panel are not very 
usual.3,4 Liver panel abnormality reported in the form of ele-
vated alkaline phosphatase (most common) in 20% to 40% of 
patients with sarcoid granulomas in the liver hardly ever causes 
symptoms in the form of hepatosplenomegaly (15%-40%) or 
lymphadenopathy (15%).5
Therefore, hepatic sarcoid can be classified into 4 groups. 
Group 1 patients have asymptomatic or incidental granulomas 
randomly found during liver biopsy or to substantiate the diag-
nosis of sarcoidosis. Group 2 patients have hepatomegaly or 
splenomegaly with evidence of mild hepatic derangement. 
Group 3 are patients with hepatocellular disease with or with-
out portal hypertension. Group 4 are patients with portal 
hypertension as the major manifestation. Advanced signs of 
liver failure like in our patient include ascites, jaundice, hepatic 
encephalopathy, and bleeding diathesis.6
Life-threatening complications of sarcoidosis are rare. The 
mortality rates were estimated to be 4.32/1 000 000 between 
1988 and 2007. Respiratory and cardiac complications are the 
most common causes of death. The leading cause of death in 
such patients is a result of pulmonary fibrosis followed by car-
diac failure. Acute fulminant hepatic failure as a complication 
of sarcoidosis is rare, with an incidence of less than 5% in 
patients with hepatic sarcoidosis.
Although glucocorticoids are the most commonly used 
therapeutic agents for sarcoidosis, patients with SCD incur the 
risk of developing severe sickle cell–related clinical manifesta-
tion during treatment with steroids.7 Delmonte et al8 reported 
a patient with sarcoidosis and SCD successfully treated with 
low-dose prednisone and methotrexate.
There are no defined protocols or recommendations for 
indications of initiation of treatment, drug choice, and dosage 
or duration of therapy in patients with hepatic sarcoidosis. 
Although there are no randomized controlled trials, steroids 
have been shown to improve clinical symptoms, liver enzymes, 
and even reduce hepatomegaly. Azathioprine and infliximab 
have also been used for maintenance therapy. However, the 
effect of these agents on the natural history of hepatic sar-
coidosis is unknown.9
Ahn et al. reported cases of sickle cell hepatopathy and 
classified the patients into 2 major groups. They defined 
sickle cell hepatopathy as serum bilirubin greater than 13 
mg/dL not explained by acute hemolysis, viral hepatitis, 
extrahepatic obstruction, or hepatic sequestration. The 
patients in the first group had milder disease with no mani-
festation of severe hepatic damage and a mean bilirubin of 
27.6 mg/dL. The patients in the second group had more 
severe hepatic dysfunction, with a mean bilirubin of 76.8 
mg/dL, accompanied by altered mental status and/or pro-
longed coagulation times. Mortality in the first group was 
4% and in the second group was 64%.10 They found exchange 
transfusion to be the only effective treatment in early cases of 
sickle cell hepatopathy.
Liver transplantation used as a management strategy for 
sickle cell hepatopathy has not been widely studied. PubMed 
search identified 10 adults and 5 children with SCD who 
underwent orthotopic liver transplantation. Of the 10 adults, 4 
died in the immediate postoperative period and 5 of the 
remaining 6 eventually died due to sickle cell–related allograft 
complications; in the pediatric group, 3 of the 5 patients sur-
vived postoperatively.11–14 In successful adult patient with 
orthotopic liver transplant, it was noted that aggressive preop-
erative and postoperative red cell transfusions (to a goal hemo-
globin of greater than 10 g/dL—requiring 2 U every 4 weeks) 
prevented sickling in the graft liver. But this also placed the 
patient at risk of iron overload.
This patient is probably the first reported case of fatal SCD 
combined with hepatic sarcoidosis. A PubMed search did not 
reveal a prior reported case of the same. His sarcoidosis could 
not be treated with steroid, which is the first-line agent because 
it flared his sickle cell crisis. This led to stopping his steroids 
and other immunomodulators, but a combination of sickling 
in liver sinusoids and active sarcoid granulomas in his liver 
resulted in acute liver failure. We wonder whether liver trans-
plantation would be the answer to this dilemma, but it would 
have probably resulted in recurrence of the disease processes in 
Laboratory values.
LABoRAToRy VALUES AT ThE TiME oF ADMiSSioN PEAkED VALUES
AST 213 U/L 7922 U/L
ALT 68 U/L 1398 U/L
Alkaline phosphatase 373 U/L 233 U/L
Total bilirubin 26.3 mg/dL 47.7 mg/dL
Direct bilirubin 22.7 mg/dL 30 mg/dL
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Nutan 3
the transplanted liver if the patient had survived the post-
transplantation period.
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